CORRIGENDUM: Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials. [Pharmacy & Pharmacology. 2025;13(1):31-44. DOI: 10.19163/2307-9266-2025-13-1-31-44]
https://doi.org/10.19163/2307-9266-2025-13-4-316
Abstract
Related to the article: Markin S.S., Ivanov S.V., Beletsky I.P., Zakharova M.V., Ponomarev E.A., Arzamascev E.V. Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials. Pharmacy & Pharmacology. 2025;13(1):31-44. https://doi.org/10.19163/2307-9266-2025-13-1-31-44
We hereby inform readers that changes have been made to the final version of the article in Russian and English.
In the published article " Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials" the authors found an error: randomly, due to a technical error and without any malicious intent, in the "Results" section, subsection "Clinical study of the effect of recombinant non-immunogenic staphylokinase on the formation of specific antibodies and neutralizing activity of patient plasma" (p. 37, second column, 4th paragraph from the top), erroneous numerical indicators were indicated: "In the study of specific antibody titers in patients with STEMI who were administered recombinant non-immunogenic staphylokinase, it was found that 30 (30%) patients did not have specific antibodies. In 70 (70%) patients, specific antibodies were detected with a low titer — in the range of 1/100–1/800."
Correct version: "In the study of specific antibody titers in patients with STEMI who were administered recombinant non-immunogenic staphylokinase, it was found that 70 (70%) patients did not have specific antibodies. In 30 (30%) patients, specific antibodies were detected with a low titer — in the range of 1/100–1/800."
This error is technical in nature, because the abstract text displays correct data, and further in the text of the article correct data are shown: "...neutralizing activity of blood plasma of patients with STEMI who were administered recombinant non-immunogenic staphylokinase revealed that samples from 70 (70%) patients did not have neutralizing activity...".
The error does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.
The authors would like to apologize for any inconvenience.
The authors declare no conflict of interest.
The original article has been updated in the online version: https://www.pharmpharm.ru/jour/article/view/1674
Supporting agencies: The work was carried out within the framework of the Program of Fundamental Scientific Research of the Russian Federation for the long-term period (2021–2030) (No. 122030100170-5). Non-immunogenic recombinant staphylokinase was provided by SuperGene LLC (Russia).
About the Authors
S. S. Markin
1. Institute of Biomedical Chemistry.
2. SuperGene.
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor, senior research associate of Institute of Biomedical Chemistry.
1. 10 Pogodinskaya Str., bldg 8, Moscow, Russia, 119435.
2. 6 Luzhnetskaya Emb., bldg 1, Moscow, Russia, 119270.
S. V. Ivanov
1. Institute of Biomedical Chemistry.
2. SuperGene.
Russian Federation
Russian Federation
Candidate of Sciences (Biology), senior research associate of Institute of Biomedical Chemistry.
1. 10 Pogodinskaya Str., bldg 8, Moscow, Russia, 119435.
2. 6 Luzhnetskaya Emb., bldg 1, Moscow, Russia, 119270.
I. P. Beletsky
Institute of Theoretical and Experimental Biophysics of Russian Academy of Sciences.
Russian Federation
Russian Federation
Doctor of Sciences (Biology), department professor, director of Institute of Theoretical and Experimental Biophysics of Russian Academy of Sciences.
3 Institutskaya Str., Pushino, Russia, 142290.
M. V. Zakharova
Skryabin Institute of Biochemistry and Physiology of Microorganisms.
Russian Federation
Russian Federation
Candidate of Sciences (Biology), leading researcher Skryabin Institute of Biochemistry and Physiology of Microorganisms of Russian Academy of Sciences.
5 Nauki Ave., Pushino, Russia, 142290.
E. A. Ponomarev
1. City Clinical Hospital of Emergency Medicine No. 25.
2. Volgograd State Medical University.
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor of Department of Hospital Surgery Volgograd State Medical University; Deputy Chief Physician for Surgical Care City Clinical Hospital of Emergency Medicine No. 25 (Volgograd, Russia).
1. 74 Zemlyachki Str., Volgograd, Russia, 400138.
2. 1, Pavshikh Bortcov Sq., Volgograd, Russia, 400066.
E. V. Arzamascev
National Medical Research Center of Cardiology named after Academician E.I. Chazov.
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor, Head of the Smirnov Laboratory of Medicinal Toxicology of National Medical Research Center of Cardiology named after Academician E.I. Chazov.
15a Academician Chazov Str., Moscow, Russia, 121552.
Review
For citations:
Markin S.S., Ivanov S.V., Beletsky I.P., Zakharova M.V., Ponomarev E.A., Arzamascev E.V. CORRIGENDUM: Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials. [Pharmacy & Pharmacology. 2025;13(1):31-44. DOI: 10.19163/2307-9266-2025-13-1-31-44]. Pharmacy & Pharmacology. 2025;13(4):316. https://doi.org/10.19163/2307-9266-2025-13-4-316
Views:
25
Email this article 